JPMorgan has reinstated ratings and price targets on 14 large-cap biotechnology companies, describing the sector as being at a critical inflection point as pipeline successes translate into profitable commercial franchises.
The bank's analysts, led by Jessica Fye, noted that several firms have already achieved sustained profitability, while others are on the verge, setting the stage for margin expansion and long-term growth.
Companies such as Alnylam Pharmaceuticals, BeOne Medicines, and Ascendis Pharma have transitioned into profitability, while Insmed and Ionis are close to doing so. JPMorgan sees diversification as another key theme, with Vertex Pharmaceuticals expanding into renal disease, BioMarin strengthening its rare disease portfolio, and Moderna applying its mRNA platform to oncology.
Analysts also pointed to a steady stream of clinical updates ahead, including high-profile cardiovascular outcomes trials for Ionis's partnered drugs and pivotal renal readouts from Vertex, which could act as catalysts for the sector.
JPMorgan rated Vertex, Alnylam, BeOne, United Therapeutics, Insmed, Ascendis, Jazz, Ionis, BioMarin, and Mirum "Overweight," while assigning "Neutral" to BioNTech, Incyte, and Halozyme. Moderna was rated "Underweight."
Price targets for December 2026 include $515 for Vertex, $420 for Alnylam, $415 for BeOne, $685 for United Therapeutics, and $180 for Insmed. Moderna was given a $40 target, while BioNTech was set at $100.
The analysts emphasized that the sector is strategically positioned for growth, with companies broadening their commercial footprints and pursuing disciplined business development.
